HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

The FDA clearance unlocks multiple growth initiatives for HeartBeam. The company plans a limited commercial launch in Q1 2026 targeting select concierge and preventive cardiology groups that have ...

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...

Riyad Mahrez's double helped Algeria to a dominant victory over 10-man Sudan in their 2025 Africa Cup of Nations Group E opener in Rabat.

“When the mouth gets really dry, it limits the buffering capacity of saliva,” Clonan said. “Saliva helps wash away whatever plaque and food products are in your mouth, prevents plaque from sticking ...

HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...

HeartBeam BEAT recently secured FDA 510(k) clearance for its first-of-its-kind, cable-free synthesized 12-lead ECG technology, marking a major inflection point in the company’s mission to modernize ...

The company notes the synthesized output is not intended to replace a standard 12-lead ECG. HeartBeam also plans to advance development of an on-demand 12-lead ECG extended wear monitor and build ...

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...

Speaking at a news briefing in Blantyre, Munlo stated that his decision to quit MCP is personal, emphasizing that he has stopped partisan politics but remains politically conscious. This suggests that ...